Stifel lowered the firm’s price target on Cipher Pharmaceuticals (CPHRF) to C$17 from C$19 and keeps a Buy rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CPHRF:
- Cipher Pharmaceuticals Q3 2024 Results: Growth and Acquisitions
- Cipher Pharmaceuticals’ Revenue Soars After Natroba Acquisition
- CPHRF Earnings this Week: How Will it Perform?
- Cipher Pharmaceuticals Announces Q3 2024 Financial Results
- Cipher Pharmaceuticals price target raised to C$19 from C$17 at Stifel
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
